Nuclear Medicine and Biology
Volume 35, Issue 7 , Pages 763-768 , October 2008

Breast tumor targeting with 99mTc-HYNIC-PR81 complex as a new biologic radiopharmaceutical

  • Mojtaba Salouti

      Affiliations

    • Department of Medical Physics, Tarbiat Modares University, Tehran, Iran
    • ,
  • Hossein Rajabi

      Affiliations

    • Department of Medical Physics, Tarbiat Modares University, Tehran, Iran
    • Corresponding Author InformationCorresponding author. Department of Medical Physics, Tarbiat Modares University, P.O. Box 14115-331, Tehran, Iran. Tel.: +98 21 82803894; fax: +98 21 88006544.
    • ,
  • Mohammad Hossein Babaei

      Affiliations

    • Department of Radioisotope, Atomic Energy Organization of Iran, Tehran, Iran
    • ,
  • Mohammad Javad Rasaee

      Affiliations

    • Department of Medical Biotechnology, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran

Received 19 May 2008 ,Revised 7 July 2008 ,Accepted 12 July 2008.

References 

  1. Clarke CA, Glaser S, West DW, Ereman RP, Erdmann CA, Barlow JM, et al. Breast cancer incidence and mortality trends in affluent population: marin county, California, USA, 1990-1999. Breast Cancer Res. 2002;4(6):R13
  2. Wiele C, Revets H, Mertens N. Radioimmunoimaging: advances and prospects. Q J Nucl Med Mol Imaging. 2004;48:317–325
  3. Sharkey RM, Goldenberg DM. Targeted therapy of cancer: prospects for antibodies and immunoconjugates. CA Cancer J Clin. 2006;56:226–243
  4. Taylor J, Burchell J, Miles DW, Dalziel M. MUC1 and cancer. Biochim Biophys Acta Mol Basis Dis. 1999;1455:301–313
  5. Kokko R, Holli K, Hakama M. CA 15.3 in the follow-up of localized breast cancer: a prospective study. Eur J Cancer. 2002;38:1189–1193
  6. Schuhmacher J, Klivenyi G, Kaul S, Henze M, Matys R, Hauser H, et al. Pretargeting of human mammary carcinoma xenografts with bispecific anti-MUC1/anti-Ga chelate antibodies and immunoscintigraphy with PET. Nucl Med Biol. 2001;28:821–828
  7. Schuhmacher J, Kaul S, Klivenyi G, Junkermann H, Magener A, Henze M, et al. Immunoscintigraphy with positron emission tomography: gallium-68 chelate imaging of breast cancer pretargeted with bispecific anti-MUC1/anti-Ga chelate antibodies. Cancer Res. 2001;61:3712–3717
  8. Albrecht H, Denardo GL, Denardo SJ. Development of anti-MUC1 di-scFvc for molecular targeting of epithelial cancers, such as breast and prostate cancers. Q J Nucl Med Mol Imaging. 2007;51:304–313
  9. Paknejad M, Rasaee MJ, Karami F, Kashanian S, Mohagheghi MA, Omidfar K. Production of monoclonal antibody, PR81, recognizing the tandem repeat region of MUC1 mucin. Hybrid Hybridomics. 2003;22(3):153–158
  10. Mohammadnejad J, Rasaee MJ, Saghafi B, Rajabibazl M, Rabarizadeh F, Omidfar K. A new competitive enzymed linked immunosorbent assay (MRP83-CA15-3) for MUC1 measurement in breast cancer. J Immunoass Immunochem. 2006;27:139–149
  11. Salouti M, Rajabi H, Babaei H, Rasaee MJ, Najafi R, Paknejad M, et al. 99mTc direct radiolabeling of PR81, a new anti-MUC1 monoclonal antibody for radioimmunoscintigraphy. Iran J Nucl Med. 2005;23:7–16
  12. Salouti M, Rajabi H, Babaei H, Rasaee MJ, Najafi R, Paknejad M, et al. A new monoclonal antibody radiopharmaceutical for radioimmunoscintigraphy of breast cancer: direct labeling of antibody and its quality control. DARU. 2006;14(1):51–56
  13. Johnstone A, Thorpe R. Immunocytochemistry, immunohistochemistry and flow cytofluorimetry. In: Immunochemistry in practice. 3rd ed.. Berlin: Blackwell Science; 1996;p. 313–338
  14. Abrams MJ, Juweid M, Tenkate CI. Technetium-99m human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J Nucl Med. 1990;31:2022–2028
  15. Larsen SK, Caldwell G, Higgins JD, Abram MS, Solomon HF. Technetium complex of tricine: useful precursor for the 99mTc labelling of hydrazino nicotinamide modified proteins. J Label Compd Radiopharm. 1994;35:1–2
  16. Mather SJ, Ellison D. Reduction mediated technetium-99m labeling of monoclonal antibodies. J Nucl Med. 1990;31:692–697
  17. Lee HJ, Pardridge W. Monoclonal antibody radiopharmaceuticals: cationization, pegylation, radiometal chelation, pharmacokinetics, and tumor imaging. Bioconjug Chem. 2003;14:546–553
  18. Price MR, Rye PD, Petrakou E. Summary report on the ISOBM TD-4 workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin. Tumor Biol. 1998;19(Suppl 1):1–20
  19. Geoffrey AP, Wenjun L, Krauer K, Baker T, Wreschner D, Mckenzie IFC. Comparison of the biological properties of two anti-mucin-1 antibodies prepared for imaging and therapy. Cancer Immunol Immunother. 1997;44:323–328
  20. Mohammadi M, Rasaee MJ, Rajabibazl M, Paknejad M, Zare M, Mohammadzadeh S. Epitope mapping of PR81 anti-MUC1 monoclonal antibody following PEPSCAN and phage display. Techniques. Hybridoma. 2007;26(4):223–229

PII: S0969-8051(08)00171-6

doi: 10.1016/j.nucmedbio.2008.07.002

Nuclear Medicine and Biology
Volume 35, Issue 7 , Pages 763-768 , October 2008

Article Tools

* Image Usage & Resolution